Skip to content
PatientMatchFind trials
Study details
Enrolling now

MM402 for Autism Spectrum Disorder

Definium Therapeutics US, Inc.
NCT IDNCT07303907ClinicalTrials.gov data as of Apr 2026
Check if I qualifyBack to resultsClinicalTrials.gov
Phase

Phase 2

Target enrollment

20

Study length

about 1.7 years

Ages

18–65

Locations

1 site in NY

About this study

Researchers are testing a treatment called MM402, which is an R-enantiomer of MDMA (R-MDMA), in adults with autism spectrum disorder. The trial will last 636 days and involve approximately 20 participants.

Based on ClinicalTrials.gov records.

What participants do

  • 1.Take MM402 (R-enantiomer of 3,4-methylenedioxymethamphetamine (MDMA))
PhasePhase 2
Routeoral
Primary goalChange from Baseline in 11-point Numerical Rating Scale (NRS) scores

Participation effort

Estimated from trial records. Details can vary by site.

Time + visits
Low4%
Logistics
Moderate50%

Logistics difficulty varies by site location and availability.

Trial highlights

Treatment details

Auto-extracted from trial records to preview treatments and outcomes.

Drug routes

oral

Endpoints

Primary: Change from Baseline in 11-point Numerical Rating Scale (NRS) scores

Secondary: Pharmacokinetic Parameters (AUC0-24h), Pharmacokinetic Parameters (AUC0-inf), Pharmacokinetic Parameters (Cmax), Pharmacokinetic Parameters (Tmax), Pharmacokinetic Parameters (t1/2), Pharmacokinetic Plasma concentrations

Body systems

Psychiatry / Mental Health

Check if I qualifyView on ClinicalTrials.gov